Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.71 |
| ▸ | KDR | P35968 | 1/20 | 0.69 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.60 |
| ▸ | PGR | P06401 | 2/20 | 0.58 |
| ▸ | FABP1 | P07148 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | ESR1 | P03372 | 1/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.54 |
| ▸ | CASP3 | P42574 | 1/20 | 0.54 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.54 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.54 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.54 |
| ▸ | AR | P10275 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6898946 | 0.93 | MEN1 (0.61) | MEN1KMT2AKDRMCHR1PGR | |
| SCHEMBL6807188 | 0.91 | MCHR1 (0.71) | MEN1KMT2AKDRMCHR1PGR | |
| SCHEMBL6811436 | 0.86 | MCHR1 (0.75) | MEN1KMT2AMCHR1PGRFABP1 | |
| SCHEMBL6893838 | 0.86 | MCHR1 (0.72) | MEN1KMT2AKDRMCHR1PGR | |
| SCHEMBL6921757 | 0.85 | KDR (0.73) | MEN1KMT2AKDRMCHR1NPC1 | |
| SCHEMBL6922563 | 0.84 | KDR (0.72) | MEN1KMT2AKDRMCHR1NPC1 | |
| SCHEMBL7051105 | 0.84 | MEN1 (0.58) | MEN1KMT2AKDRMCHR1NPC1 | |
| SCHEMBL12531267 | 0.81 | MCHR1 (0.54) | MEN1KMT2AKDRMCHR1PGR | |
| SCHEMBL14964397 | 0.81 | MCHR1 (0.64) | MEN1KMT2AKDRMCHR1PGR | |
| SCHEMBL12531372 | 0.80 | MCHR1 (0.53) | MEN1KMT2AKDRMCHR1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063686-A1 | Carboxamide compounds and their use as antagonists of a human 11cby receptor | JOHNSON CHRISTOPHER NORBERT (GB) | 2004-04-01 | — | — | US | claimed |
| EP-1305304-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS ANTAGONISTS OF A HUMAN 11CBY RECEPTOR | SMITHKLINE BEECHAM PLC (GB) | 2003-05-02 | — | — | EP | claimed |
| WO-2002010146-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS ANTAGONISTS OF A HUMAN 11CBY RECEPTOR | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-02-07 | — | — | WO | claimed |
| EP-1100485-A4 | SUBSTITUTED ANILIDE COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2004-06-09 | — | — | EP | disclosed |
| US-20040063686-A1 | Carboxamide compounds and their use as antagonists of a human 11cby receptor | JOHNSON CHRISTOPHER NORBERT (GB) | 2004-04-01 | — | — | US | disclosed |
| EP-1305304-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS ANTAGONISTS OF A HUMAN 11CBY RECEPTOR | SMITHKLINE BEECHAM PLC (GB) | 2003-05-02 | — | — | EP | disclosed |
| WO-2002010146-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS ANTAGONISTS OF A HUMAN 11CBY RECEPTOR | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-02-07 | — | — | WO | disclosed |
| EP-1100485-A1 | SUBSTITUTED ANILIDE COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000006146-A9 | SUBSTITUTED ANILIDE COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2000-08-03 | — | — | WO | disclosed |
| WO-2000006146-A1 | SUBSTITUTED ANILIDE COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063686-A1 | Carboxamide compounds and their use as antagonists of a human 11cby receptor | CNR1, GPR3, CCKAR | MEN1 855/4885KMT2A 1297/4885KDR 1785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.